Interleukin-2 (IL-2) with 13-cis retinoic acid (RA) to prolong disease free and overall survival in metastatic colorectal cancer

3629 Background: In a phase 1B study we established that low-dose IL-2 and 13-cis retinoic acid was not toxic and could be administered safely as maintenance therapy for patients (PTS) exhibiting r...